Hiscl m2bpgi

All routine laboratory data were collected immediately before the first NA treatment and serially during the treatment. Serum M2BPGi level was measured using serum samples that had been stored at −20 °C. M2BPGi quantification was performed by an immunoassay using a commercially available kit (HISCL M2BPGi; Sysmex Co., Kobe, Japan) and a fully automatic immunoanalyzer (HISCL-5000; Sysmex Co.). Serum HBV viral load was determined using a COBAS TaqMan HBV test v2.0 (Roche Diagnostics, Branchburg, NJ), which has a dynamic range of 2.1–9.0 log copies (LC)/mL. Quantitative measurements of HBsAg, Hepatitis B e-antigen (HBeAg), and hepatitis B core-related antigen (HBcrAg) were conducted using commercial chemiluminescent enzyme immunoassay kits.

All routine laboratory data were collected immediately before treatment. The APRI and FIB-4 index was calculated as previously described [19 (link),20 (link)]. Serum WFA⁺-M2BP level was measured using the pretreatment serum samples stored at −20 °C. WFA⁺-M2BP quantification was performed by a WFA-antibody immunoassay using a commercially available kit (HISCL M2BPGi; Sysmex Co., Kobe, Japan) and a fully automatic immunoanalyzer (HISCL-5000; Sysmex Co.). SVR was defined as negative for serum HCV RNA at 24 weeks after EOT.
Of the 355 patients, 333 underwent ultrasonography-guided percutaneous liver biopsies just before treatment initiation. Paraffin-embedded liver-biopsy specimens were stained with hematoxylin-eosin, Azan-Mallory, and reticulin silver impregnation, and were evaluated by an experienced pathologist who was blinded to patient-clinical data according to the Metavir classification system [35 (link)].